Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over

This article was originally published in The Pink Sheet Daily

Executive Summary

Seeing no clear path to approval in the US or Europe for its muscular dystrophy drug drisapersen, BioMarin shelves it , plus three first-generation follow-on products. But it continues to "explore" its early stage next-generation oligonucleotides as potential treatments for DMD.

Advertisement

Related Content

PTC To Appeal Translarna's Complete Response Letter From US FDA
How Accelerated Approval Works – And How It Doesn't
Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel